We claim:

1. Use of a compound selected from 21-methoxy- 17α-acetoxy- 11β-(4 N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione in the manufacture of a medicament for the treatment of endometriosis or uterine fibroids in a female in need thereof, wherein the medicament contains between 3.125 mg and 12.5 mg compound and is for once per day administration to the vaginal mucosa of the female for a period of at least 4 months.
2. Use according to claim 1 wherein the medicament comprises a bioadhesive carrier and is in the form of a gel, cream, tablet, pill, capsule or suppository.
3. Use according to claim 1 wherein the medicament is to be administered for a period of at least 12 months.
4. Use according to claim 1, wherein the medicament comprises 21 -methoxy- 17α-acetoxy-11β-(4 N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione.
5. Use according to claim 1, wherein the medicament comprises 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione.

Claims:

1. Use of a compound selected from 21 -methoxy- 17α-acetoxy- 11β-(4 N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione in the manufacture of a medicament for the treatment of endometriosis or uterine fibroids in a human female in need thereof, wherein the medicament contains between 3.125 mg and 12.5 mg compound and is for once per day administration to the vaginal mucosa of the human female for a period of at least 4 months.

2. Use according to claim 1 wherein the medicament comprises a bioadhesive carrier and is in the form of a gel, cream, tablet, pill, capsule or suppository.

3. Use according to claim 1 wherein the medicament is to be administered for a period of at least 12 months.

4. Use according to claim 1, wherein the medicament comprises 21 -methoxy- 17α-acetoxy-11β-(4 N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione.

5. Use according to claim 1, wherein the medicament comprises 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione.